Studies of prostate-cancer mortality: caution advised

The Lancet Oncology

Volumn 9, Issue 5, 2008, Pages 407-409

  Etzioni, Ruth ^a   Feuer, Eric ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURGERY; EARLY DIAGNOSIS; FALSE NEGATIVE RESULT; FREQUENCY ANALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; SURGICAL TECHNIQUE; UNITED KINGDOM; UNITED STATES;

AGE DISTRIBUTION; EPIDEMIOLOGIC RESEARCH DESIGN; GREAT BRITAIN; HUMANS; INCIDENCE; LINEAR MODELS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RESIDENCE CHARACTERISTICS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 42649090467     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70112-8     Document Type: Letter

References (12)

1. Collin S., Martin R., Metcalfe C., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9 (2008) 445-452
2. Shibata A., Ma J., and Whittemore A. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90 (1998) 1230-1231
3. Quinn M. Cancer trends in the United States-a view from Europe. J Natl Cancer Inst 95 (2003) 1258-1261
4. Oliver S., Gunnell D., and Donovan J. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355 (2000) 1788-1789
5. Shibata A., and Whittemore A. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 93 (2001) 1109-1110
6. Lu-Yao G., Albertsen P., Stanford J., et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325 (2002) 740
7. Shaw P., Etzioni R., Zeliadt S., et al. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States. Am J Epidemiol 160 (2004) 1059-1069
8. Baade P., Coory M., and Aitken J. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control 15 (2004) 237-241
9. Bartsch G., Horninger W., Klocker H., et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417-424
10. Horninger W., Berger A., Pelzer A., et al. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 5 (2004) 220-225
11. Harris R., and Lohr K. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med 137 (2002) 917-929
12. Etzioni R., Tsodikov A., Mariotto A., et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 19 (2008) 175-181